Resistance to cisplatin: how to deal with the problem?

[1]  C. Begg,et al.  A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Ozols,et al.  Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. , 1989, Journal of the National Cancer Institute.

[3]  S. Howell,et al.  Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. , 1989, European journal of cancer & clinical oncology.

[4]  N. Suzuki,et al.  Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell line. , 1989, European journal of cancer & clinical oncology.

[5]  A. Fojo,et al.  Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. , 1988, Cancer research.

[6]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[7]  R. Perez-soler,et al.  Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles. , 1988, Cancer research.

[8]  M. Gore,et al.  High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. , 1987, European journal of cancer & clinical oncology.

[9]  A. Eastman,et al.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. , 1987, Cancer research.

[10]  Y. Ostchega,et al.  High-dose carboplatin in refractory ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R C Young,et al.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. , 1987, Cancer research.

[12]  B. Teicher,et al.  Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[13]  Y. Ostchega,et al.  High-dose cisplatin in hypertonic saline in refractory ovarian cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Winker,et al.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. , 1985, Biochemical pharmacology.